301230SZSE

Announcement on the Results of the First Vesting Period of the 2024 Restricted Stock Incentive Plan by Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd.

Hongbo Pharmaceutical Co., Ltd.··15 pages

✨ AI Summary

Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. announced the results of the first vesting period for its 2024 restricted stock incentive plan. A total of 308,000 shares will vest to 23 participants on May 28, 2026. The plan allows for no additional lock-up period post-vesting for senior management. The company has confirmed compliance with all necessary conditions for this vesting.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· azure_openai

Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without any false records, misleading statements, or major omissions.

Important Content Reminder:

  1. Vesting Date: May 28, 2026
  2. Number of Shares Vesting: 308,000 shares
  3. Number of Participants: 23 individuals
  4. Listing and Circulation Arrangement for the Vested Shares: There will be no additional lock-up period after the vesting of the restricted shares granted under this incentive plan. Senior management participants will comply with relevant regulations.

On April 27, 2026, the Company held the seventh meeting of the fourth Board of Directors, which reviewed and approved the proposal regarding the achievement of the vesting conditions for the first vesting period of the initial grant of the 2024 restricted stock incentive plan. Recently, the Company has completed the vesting registration for the first vesting period of the initial grant of the 2024 restricted stock incentive plan for 23 participants, with a total vesting quantity of 308,000 shares. The relevant matters are explained as follows:

I. Overview of the Implementation of the Equity Incentive Plan

(1) Brief Description of the Incentive Plan

On November 18, 2024, the Company held the third extraordinary general meeting of shareholders in 2024, which reviewed and approved the "Draft of the 2024 Restricted Stock Incentive Plan of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd." (hereinafter referred to as "the Incentive Plan"). The main contents are as follows:

  • Incentive Tool: Restricted Stock (Type II Restricted Stock).
  • Source of Target Shares: The Company’s A-share common stock repurchased from the secondary market and/or A-share common stock issued to the incentive participants.
  • Grant Price: 12.35 yuan/share.
  • Participants and Distribution: A total of 28 individuals are proposed to be granted under this incentive plan, including senior management and core technical (business) backbones employed by the Company (including subsidiaries) at the time of the announcement of this incentive plan. The specific distribution is shown in the table below:

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.